



NDA 20-441/S-017

AstraZeneca LP
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803-8355

Attention: Christopher M. Blango
Regulatory Affairs Director

Dear Mr. Blango:

Please refer to your supplemental new drug application dated March 27, 2002, received March 28, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pulmicort Turbuhaler (budesonide inhalation powder).

This supplemental new drug application provides for the removal of the black box surrounding the warning about the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression when patients are switched from systemic corticosteroids to inhaled corticosteroids. .

We completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

When you submit the final printed labeling for this supplement (package insert submitted March 27, 2002) you may incorporate the changes provided for in S-016 approved on October 24, 2003.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-441/S0-16 and S-017." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Colette Jackson, Regulatory Project Manager, at (301) 827-5584.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Division Director
Division of Pulmonary and Allergy Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Badrul Chowdhury
12/17/03 02:33:06 PM